Ferreira JP, Claggett BL, Liu J, et al. - In this study, the relationship between serum potassium and clinical outcomes was explored in the PARAGON‐HF trial in which 4,822 patients with heart failure and preserved ejection fraction (HFpEF) were randomized to treatment with sacubitril/valsartan or valsartan. Researchers assessed the association between serum potassium concentrations and the primary study composite outcome of total (first and recurrent) heart failure hospitalizations and cardiovascular death. The data exhibited that both hypo‐ and hyperkalemia were correlated with heart failure hospitalization but only hypokalaemia was correlated with mortality, especially in the context of renal impairment. It was shown that hypokalaemia was as strongly correlated with death from non‐cardiovascular causes as with cardiovascular death. The data imply that potassium disturbances are more of a marker of HFpEF severity rather than a direct cause of death.